Steward Partners Investment Advisory’s Acceleron Pharma XLRN Stock Holding History

Steward Partners Investment Advisory’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$52K	–	3402
2021 Q3	$52K	Hold	300	–	–	﹤0.01%	1883
2021 Q2	$38K	Hold	300	–	–	﹤0.01%	3854
2021 Q1	$40.7K	Hold	300	–	–	﹤0.01%	2088
2020 Q4	$38K	Hold	300	–	–	﹤0.01%	1804
2020 Q3	$34K	Hold	300	–	–	﹤0.01%	1676
2020 Q2	$29K	Hold	300	–	–	﹤0.01%	1638
2020 Q1	$26K	Hold	300	–	–	﹤0.01%	1515
2019 Q4	$15K	Hold	300	–	–	﹤0.01%	1881
2019 Q3	$11K	Hold	300	–	–	﹤0.01%	1968
2019 Q2	$12K	Buy	+300	New	+$12.4K	﹤0.01%	1913
2018 Q4	–	Sell	-300	Closed	-$17K	–	2406
2018 Q3	$17K	Buy	+300	New	+$14.7K	﹤0.01%	1641

Steward Partners Investment Advisory's XLRN Position: Q4 2021 in Review

Steward Partners Investment Advisory sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 300 shares — an estimated $52K sold.

Steward Partners Investment Advisory first reported a position in XLRN in Q3 2018 and held it in 11 quarters. The position peaked at $52K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Steward Partners Investment Advisory reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Steward Partners Investment Advisory sold 300 Acceleron Pharma shares in Q4 2021, an estimated $52K.
Steward Partners Investment Advisory first reported a position in Acceleron Pharma in Q3 2018 and held it in 11 quarters.
Steward Partners Investment Advisory's Acceleron Pharma position peaked at $52K in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2021, filed 8 Feb 2022.